The biomanufacturing industry is increasingly interested in continuous manufacturing solutions that can reduce the manufacturing footprint and improve supply chain logistics and biotherapeutic access by enabling manufacturing to move closer to patients, especially in underserved areas. The NIIMBL mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, which will fundamentally advance U.S. competitiveness in the industry.
“Agilent has long played a key role in providing trusted answers for the analytical needs of the biopharmaceutical industry,” said Agilent CEO Mike McMullen. “The prominence of biopharmaceuticals coupled with the advent of precision cell and gene biotherapeutics has further spurred the need for innovative measurement tools to help deliver life-saving drugs and diagnostics to patients.”
Agilent’s online HPLC sampling portfolio, cellular imaging, and real-time sensor technologies exemplify how the company can help address current and emerging needs. Additionally, Agilent’s NIIMBL membership will allow us to work closely with all continuum partners to help shape the future of innovation and standards used in bioprocess development and biomanufacturing.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.
Related Links : https://www.agilent.com/about/newsroom/presrel/2022/19apr-ca22013.html